A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice

Witjes, 2021, European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines, Eur Urol, 79, 82, 10.1016/j.eururo.2020.03.055 Netherlands Cancer Registry (NCR) NCCOI. www.iknl.nl/en/ncr/ncr-data-figures James, 2012, Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 366, 1477, 10.1056/NEJMoa1106106 Giacalone, 2017, Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience, Eur Urol, 71, 952, 10.1016/j.eururo.2016.12.020 Rodel, 2002, Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results, J Clin Oncol, 20, 3061, 10.1200/JCO.2002.11.027 Arcangeli, 2015, A systematic review of radical cystectomy versus organ preserving trimodal therapy in muscle-invasive bladder cancer, Int J Radiat Oncol Biol Phys, 93, S24, 10.1016/j.ijrobp.2015.07.061 Fahmy, 2018, A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer, Urol Oncol, 36, 43, 10.1016/j.urolonc.2017.10.002 Pos, 2009, Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancer, Radiother Oncol, 93, 364, 10.1016/j.radonc.2009.09.003 Voskuilen, 2020, Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: a convenient alternative to 5-fluorouracil, Radiother Oncol, 150, 275, 10.1016/j.radonc.2020.07.057 National Cancer Institute (NCI)/National Institute of Health (NIH). Common terminology criteria for adverse events v.5.0 (CTCAE). 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf Mak, 2014, Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233, J Clin Oncol, 32, 3801, 10.1200/JCO.2014.57.5548 El-Achkar, 2018, Bladder preservation therapy: review of literature and future directions of trimodal therapy, Curr Urol Rep, 19, 108, 10.1007/s11934-018-0859-z Khalifa, 2021, Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder, Radiother Oncol, 161, 95, 10.1016/j.radonc.2021.06.011 Horwich, 2019, EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees, Ann Oncol, 30, 1697, 10.1093/annonc/mdz296 Arafat, 2016, Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients, Ecancermedicalscience, 10, 682, 10.3332/ecancer.2016.682 Zhang, 2015, Radiotherapy in muscle-invasive bladder cancer: The latest research progress and clinical application, Am J Cancer Res, 5, 854 Jones, 2018, Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort, Int J Radiat Oncol Biol Phys, 101, 1202, 10.1016/j.ijrobp.2018.04.033 Sell, 1991, Scand J Urol Nephrol Suppl, 138, 193, 10.1080/21681805.1991.12068888 Miller, 1977, Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C, Cancer, 39, 973, 10.1002/1097-0142(197702)39:2+<973::AID-CNCR2820390737>3.0.CO;2-O Huddart, 2017, Clinical and patient-reported outcomes of SPARE—a randomised feasibility study of selective bladder preservation versus radical cystectomy, BJU Int, 120, 639, 10.1111/bju.13900 Wettstein, 2019, Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: does the current quality of evidence justify definitive conclusions?, PLoS One, 14, e0216255, 10.1371/journal.pone.0216255 van Dijk, 2020, Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial, Nat Med, 26, 1839, 10.1038/s41591-020-1085-z Powles, 2019, Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial, Nat Med, 25, 1706, 10.1038/s41591-019-0628-7 Necchi, 2020, Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies, Eur Urol, 77, 439, 10.1016/j.eururo.2019.10.026 van Hattum, 2021, Bladder-sparing chemoradiotherapy combined with immune checkpoint inhibition for locally advanced urothelial bladder cancer—a review, Cancers (Basel), 14, 38, 10.3390/cancers14010038